CORE-- NEUROPATHOLOGY

神经病理学核心的目标是提供技术资源， 实验室设施和收集的专业知识， 从病人尸检中获得的脑组织的诊断和储存 印第安纳州ADC临床中心的对照受试者研究， 以及其他机构转介的个案。 神经病理学 核心将提供有关病理数据的家庭信息， 转诊医生和基础研究人员。 此外，核心将 参与社区的继续教育，了解新的 阿尔茨海默病（AD）研究的新进展。 我们对分子，生物化学，组织化学， AD的病理和临床方面在20世纪60年代迅速发展， 过去五年 因此，痴呆症患者的脑组织必须 研究诊断和研究目的使用多学科 approach. 我们建立了痴呆症实验室， 脑退化性疾病的形态测量研究实验室， 扩大了我们的大脑银行 “核心”为调查作出了贡献 遗传性早老性痴呆伴神经系统缠结的研究， 表征具有APP基因突变的家族性AD，（ii） 表征Gerstmann-Straussler的神经病理表型， 印第安纳州家族中的Schkeinker（GSS）病，（iii）研究tau蛋白 神经退行性疾病的病理学，（iv）扩大我们对 APP和PRNP突变引起的疾病的神经病理学 基因，（五）发现新形式的老年痴呆症。 我们正在扩大我们的使命，整合现代分子技术， 协助诊断痴呆症，特别是大脑 淀粉样变性 事实上，我们正在结合神经形态学获得的数据， 免疫组织化学和免疫细胞化学来识别和 表征分子的定位和抗原谱， 在成人痴呆的发病机制中起重要作用。 这 分析是探索表型异质性的基础。 此外，通过使用尸检获得的脑组织以及 石蜡包埋材料，我们将定义的分子遗传学 个别案件。 具体来说，我们将使用技术，使我们能够 识别目前已知导致AD的基因中描述的突变， 其他痴呆症 我们认为，这种多学科方法 ADC神经病理学核心所需，以在 组织学、生物化学和DNA水平，充分利用 收集的材料。

The aims of the Neuropathology Core are to provide technical resources, laboratory facilities and professional expertise for the collection, diagnosis and storage of brain tissue obtained at autopsy from patients and control subjects studies in the Clinical Core of the Indiana ADC, as well as from referral cases from other institutions. The Neuropathology Core will provide information about pathologic data to families, referring physicians and basic researchers. In addition, the Core will be involved in continuing education to the community about new developments emerging from Alzheimer disease (AD) research. Our understanding of the molecular, biochemical, histochemical, pathologic and clinical aspects of AD has advanced rapidly during the last five years. Thus, brain tissue of demented individuals must be studied for diagnostic and research purposes using a multidisciplinary approach. We have established a Dementia Laboratory, developed a laboratory for morphometric studies of degenerative brain diseases and expanded our Brain Bank. The Core has contributed to the investigations of hereditary presenile dementias with neurofibrillary tangles by (i) characterizing familial AD with a mutation in APP gene, (ii) characterizing the neuropathologic phenotype of Gerstmann-Straussler- Sckeinker (GSS) disease in the Indiana kindred, (iii) studying tau pathology in neurodegenerative disease, (iv) expanding our knowledge on the Neuropathology of diseases caused by mutations in the APP and PRNP genes, (v) discovering new forms of presenile dementias. We are expanding our mission integrating modern molecular technology to assist in the diagnosis of dementias, in particular the cerebral amyloidoses. In fact, we are combining data obtained by neuromorphology, immunohistochemistry, and immunocytochemistry to recognize and characterize the localization and the antigenic profile of molecules that are important to the pathogenesis of dementia of the adult. This analysis is fundamental to explore phenotypic heterogeneity. Furthermore, by using brain tissue obtained at autopsy as well as from paraffin embedded material, we will define the molecular genetics of individual cases. Specifically, we will use technology that allows us to recognize mutations described in genes currently known to cause AD and other dementias. We consider that this multidisciplinary approach required for an ADC Neuropathology Core to provide diagnosis at the histological, biochemical and DNA level, taking full advantage of the collected material.